Priority Application of Novel Materials and Nanotechnologies in Pharmaceutical Industry

Abstract:

This paper focuses on the prospects for using new materials and nanotechnologies in pharmacology and pharmaceutical industry. The authors systematize science and technology priorities of the global pharmacology and determine the perquisites for the application of the technologies emerging in the production of pharmaceutical products. The study has been conducted using the method of critical technologies. The object of the study is the thematic science and technology focus area “Hybrid materials, convergent technologies, biomimetic materials and medical supplies”. Based on the findings, the authors have drawn a number of conclusions within the frameworks of the monitoring of science and technology development of priorities implemented by a network of centers for industrial foresight. Besides, the authors have analyzed the implementation of the existing approaches to the definition of critical technologies in the context of Russia’s pharmaceutical industry. Moreover, the authors have determined the conditions for application of the method of critical technologies in the Russian pharmaceutical industry based on the thematic research and development focus area “new materials and nanotechnologies”.

• Periodical: Key Engineering Materials (Volume 683)
• Pages: 462-468
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.683.462
• Online since: February 2016
• Authors: Pyotr P. Shchetinin*, Natalia Skrylnikova, Anna V. Lozhnikova, Mikhail Chikov, Natalia Redchikova
• Keywords: Biotarget, Critical Technologies, Drug, Foresight, Intelligent Medicines, Mechanical Medicine, Medicine, Molecular Pharmacology, New Molecular Compounds, Targeted Drug Delivery Systems

References

[1] N. Shut, F. Dzhabr, K. Kharmon, S. Perkins, The medicine of the future, In the World of Science [V mire nauki – in Russian]. 7 (2012) 54-61.

[2] Clinical Pharmacology in Health Care, Teaching and Research, Council for International Organizations of Medical Sciences, Geneva, (2012).

[3] S.W. Omta, Critical Success Factors in Biomedical Research and Pharmaceutical Innovation, Springer, (2012).

[4] B.A. Bimber, S.W. Popper, What is a Critical Technology?, RAND, DRU46054CTI, Santa Monica, CA, (1994).

[5] C. Brinsmead, Skills needs for biomedical research creating the pools of talent to win the innovation race, Association of the British Pharmaceutical Industry, UK, (2010).

[6] N. Ya. Golovenko, The framework of the future of pharmacology, Pharmacol. & Medicine Toxicol. [Farmakologiya i lekarstvennaya toksikologiya – in Russian]. 6(36) (2013), Available at: http: /pharmtox-j. org. ua/node/160.

[7] P.D. Shabanov, Medicines of the third millennium, Russian Pharmacies [Rossiyskiye apteki – in Russian]. 7-8 (2013) 6-9.

[8] N.N. Karkishchenko, Innovative drugs and non-lethal technologies of the 21st century, Biomedicine [Biomeditsina – in Russian]. 1(3) (2006) 5-21.

[9] N. Savchuk, Pharmacology of the future, PBWM. ru [in Russian], 2012, Available at: http: /pbwm. ru/outlook-2013/farmakologiya-buduschego.

[10] Strategy for the Development of the Pharmaceutical Industry in the Russian Federation for the period up to 2020, Ministry for Industry and Trade, Moscow [in Russian], (2009).

[11] E. Ukusova, D. Chuvelev, N. Bykova, et al., Pharma 2020: Problems and Prospects, Park-Media Publ., Moscow [in Russian], 2009, Available at: http: /www. strf. ru/Attachment. aspx?Id=14838.

[12] Information on http: /www. prognoz2030. hse. ru.

[13] Strategic Research Program, Technology Platform Medicine of the Future, Tomsk [in Russian], 2013, Available at: http: /tp-medfuture. ru.

[14] Information on https: /www. gov. uk/government/publications/pharmaceutical-price-regulation-scheme-(2014).

[15] Information on http: /www. rusnanonet. ru/docs/index. php?by=docdate&order=asc.

[16] Information on http: /www. consultant. ru/document/cons_doc_LAW_126186.

[17] Information on http: /www. consultant. ru/document/cons_doc_LAW_164841.